ppanPersonalized Psychiatry and NeurologyPersonalized Psychiatry and Neurology2712-9179V. M. Bekhterev National Medical Research Centre for Psychiatry and Neurology of the Ministry of Health of the Russian Federation (Bekhterev NMRC PN)10.52667/2712-9179-2026-6-1-3-14ppan-159Research ArticleREVIEWThe Regulatory Role of microRNAs in the Therapeutic Response to Statins: Narrative ReviewMarilovtcevaOlga V.

Krasnoyarsk 660022

KhomchenkovRoman V.

Krasnoyarsk 660022

PetrovaMarina M.

Krasnoyarsk 660022

stk99@yandex.ruKrasnoyarsk State Medical UniversityRussian Federation20261603202616314Copyright © Marilovtceva O.V., Khomchenkov R.V., Petrova M.M., 20262026Marilovtceva O.V., Khomchenkov R.V., Petrova M.M.Marilovtceva O.V., Khomchenkov R.V., Petrova M.M.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.jppn.ru/jour/article/view/159

Statins or 3-hydroxy-3-methylglutaryl coenzyme A inhibitors are a class of cholester-ol-lowering drugs that are widely used in clinical practice for primary and secondary prevention of cardiovascular and cerebrovascular diseases associated with atherosclerosis. In recent years, there has been an increase in scientific and clinical interest in studying the relationship between statins and non-regulating ribonucleic acids circulating in the systemic bloodstream, known as circulating microRNAs. On the one hand, microRNAs play a crucial role in regulating the ex-pression of genes associated with the therapeutic response to statins, including the expression of key isoenzymes of statin metabolism in the liver, as well as directly and indirectly regulate the metabolism of high-density lipoproteins (HDL), low-density lipoproteins (LDL) and very low-density lipoproteins (VLDL). On the other hand, statins can affect the expression levels of specific microRNAs circulating in the systemic bloodstream and affecting the epigenetic mecha-nisms regulating the expression of genes encoding key pathways of atherogenesis. This narrative review provides an update on the understanding of microRNAs' role as epigenetic regulators of interindividual differences in the therapeutic response to statins, as well as their potential as next-generation lipid-lowering medications in the long run. The influence of statins on altering the expression of microRNAs involved in various mechanisms of atherogenesis is also high-lighted.

atherosclerosisstatinepigenetic biomarkerefficacysafetypersonalized therapyReferencesJellinger P.S., Smith D.A., Mehta A.E., et al. American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr. Pr. 2012; 18: 1–78. https://doi.org/10.4158/EP.18.S1.1Jellinger P.S., Smith D.A., Mehta A.E., et al. American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr. Pr. 2012; 18: 1–78. https://doi.org/10.4158/EP.18.S1.1Kucher A.N., Nazarenko M.S. The role of microRNA in atherogenesis. Kardiologiia. 2017; 57(9): 65–76. (In Russian)Kucher A.N., Nazarenko M.S. The role of microRNA in atherogenesis. Kardiologiia. 2017; 57(9): 65–76. (In Russian)Mancini G.B., Baker S., Bergeron J., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016) Can. J. Cardiol. 2016; 32: 35–65. https://doi.org/10.1016/j.cjca.2016.01.003Mancini G.B., Baker S., Bergeron J., et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Consensus Working Group Update (2016) Can. J. Cardiol. 2016; 32: 35–65. https://doi.org/10.1016/j.cjca.2016.01.003Santovito D., Egea V., Weber C. Small but smart: MicroRNAs orchestrate atherosclerosis development and progression. Biochim Biophys Acta. 2016; 1861(12 Pt B): 2075-2086. https://doi.org/10.1016/j.bbalip.2015.12.013Santovito D., Egea V., Weber C. Small but smart: MicroRNAs orchestrate atherosclerosis development and progression. Biochim Biophys Acta. 2016; 1861(12 Pt B): 2075-2086. https://doi.org/10.1016/j.bbalip.2015.12.013Aryal B., Singh A.K., Rotllan N., et al. MicroRNAs and lipid metabolism. Curr Opin Lipidol. 2017;28(3):273-280. https://doi.org/10.1097/MOL.0000000000000420,Aryal B., Singh A.K., Rotllan N., et al. MicroRNAs and lipid metabolism. Curr Opin Lipidol. 2017;28(3):273-280. https://doi.org/10.1097/MOL.0000000000000420,Keshavarz R., Reiner Ž., Zengin G., et al. MicroRNA-mediated regulation of LDL receptor: Biological and pharmacological implications. Curr Med Chem. 2024; 31(14): 1830-1838. https://doi.org/10.2174/0929867330666230407091652Keshavarz R., Reiner Ž., Zengin G., et al. MicroRNA-mediated regulation of LDL receptor: Biological and pharmacological implications. Curr Med Chem. 2024; 31(14): 1830-1838. https://doi.org/10.2174/0929867330666230407091652Wagschal A., Najafi-Shoushtari S.H., Wang L., et al. Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med. 2015; 21(11): 1290-1297. https://doi.org/10.1038/nm.3980Wagschal A., Najafi-Shoushtari S.H., Wang L., et al. Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med. 2015; 21(11): 1290-1297. https://doi.org/10.1038/nm.3980Balasubramanian R., Maideen N.M.P. HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters - An overview. Curr Drug Metab. 2021; 22(5): 328-341. https://doi.org/10.2174/1389200222666210114122729Balasubramanian R., Maideen N.M.P. HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters - An overview. Curr Drug Metab. 2021; 22(5): 328-341. https://doi.org/10.2174/1389200222666210114122729Xiang Q., Chen S.-Q., Ma L.-Y., et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myo-pathy: A meta-analysis. Pharm. J. 2018; 18: 721–729. https://doi.org/10.1038/s41397-018-0054-0Xiang Q., Chen S.-Q., Ma L.-Y., et al. Association between SLCO1B1 T521C polymorphism and risk of statin-induced myo-pathy: A meta-analysis. Pharm. J. 2018; 18: 721–729. https://doi.org/10.1038/s41397-018-0054-0Ramsey L.B., Johnson S.G., E Caudle K., et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin. Pharmacol. Ther. 2014; 96: 423–428. https://doi.org/10.1038/clpt.2014.125Ramsey L.B., Johnson S.G., E Caudle K., et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin. Pharmacol. Ther. 2014; 96: 423–428. https://doi.org/10.1038/clpt.2014.125Torres-Paz Y.E., Gamboa R., Fuentevilla-Álvarez G., et al. Involvement of expression of miR33-5p and ABCA1 in human peripheral blood mononuclear cells in coronary artery disease. Int J Mol Sci. 2024; 25(16): 8605. https://doi.org/10.3390/ijms25168605Torres-Paz Y.E., Gamboa R., Fuentevilla-Álvarez G., et al. Involvement of expression of miR33-5p and ABCA1 in human peripheral blood mononuclear cells in coronary artery disease. Int J Mol Sci. 2024; 25(16): 8605. https://doi.org/10.3390/ijms25168605El Saadany T., van Rosmalen B., Gai Z., et al. microRNA-206 modulates the hepatic expression of the organic ani-on-transporting polypeptide 1B1. Liver Int. 2019; 39(12): 2350-2359. https://doi.org/10.1111/liv.14212.El Saadany T., van Rosmalen B., Gai Z., et al. microRNA-206 modulates the hepatic expression of the organic ani-on-transporting polypeptide 1B1. Liver Int. 2019; 39(12): 2350-2359. https://doi.org/10.1111/liv.14212.Xu Y., Hu J., Zhang Y., et al. LncRNA HOTAIR modulates the expression of OATP1B1 in HepG2 cells by sponging miR-206/miR-613. Xenobiotica. 2020; 50(12): 1494-1500. https://doi.org/10.1080/00498254.2020.1777484Xu Y., Hu J., Zhang Y., et al. LncRNA HOTAIR modulates the expression of OATP1B1 in HepG2 cells by sponging miR-206/miR-613. Xenobiotica. 2020; 50(12): 1494-1500. https://doi.org/10.1080/00498254.2020.1777484Peng J.F., Liu L., Guo C.X., et al. Role of miR-511 in the regulation of OATP1B1 expression by free fatty acid. Biomol Ther (Seoul). 2015; 23(5): 400-406. https://doi.org/10.4062/biomolther.2015.010Peng J.F., Liu L., Guo C.X., et al. Role of miR-511 in the regulation of OATP1B1 expression by free fatty acid. Biomol Ther (Seoul). 2015; 23(5): 400-406. https://doi.org/10.4062/biomolther.2015.010Krattinger R., Boström A., Schiöth H.B., et al. microRNA-192 suppresses the expression of the farnesoid X receptor. Am J Physiol Gastrointest Liver Physiol. 2016; 310(11): G1044-51. https://doi.org/10.1152/ajpgi.00297.2015Krattinger R., Boström A., Schiöth H.B., et al. microRNA-192 suppresses the expression of the farnesoid X receptor. Am J Physiol Gastrointest Liver Physiol. 2016; 310(11): G1044-51. https://doi.org/10.1152/ajpgi.00297.2015Barbier R.H., McCrea E.M., Lee K.Y., et al. Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p. Sci Rep. 2021; 11(1): 10765. https://doi.org/10.1038/s41598-021-90143-4Barbier R.H., McCrea E.M., Lee K.Y., et al. Abiraterone induces SLCO1B3 expression in prostate cancer via microRNA-579-3p. Sci Rep. 2021; 11(1): 10765. https://doi.org/10.1038/s41598-021-90143-4Amponsah P.S., Fan P., Bauer N., et al. microRNA-210 overexpression inhibits tumor growth and potentially reverses gem-citabine resistance in pancreatic cancer. Cancer Lett. 2017;388:107-117. https://doi.org/10.1016/j.canlet.2016.11.035.Amponsah P.S., Fan P., Bauer N., et al. microRNA-210 overexpression inhibits tumor growth and potentially reverses gem-citabine resistance in pancreatic cancer. Cancer Lett. 2017;388:107-117. https://doi.org/10.1016/j.canlet.2016.11.035.Cao Y.X., Wen F., Luo Z.Y., et al. Downregulation of microRNA let-7f mediated the Adriamycin resistance in leukemia cell line. J Cell Biochem. 2020; 121(10): 4022-4033. https://doi.org/10.1002/jcb.29541Cao Y.X., Wen F., Luo Z.Y., et al. Downregulation of microRNA let-7f mediated the Adriamycin resistance in leukemia cell line. J Cell Biochem. 2020; 121(10): 4022-4033. https://doi.org/10.1002/jcb.29541https://go.drugbank.comhttps://go.drugbank.comhttps://www.clinpgx.org/pathwayhttps://www.clinpgx.org/pathwayRocha K.C., Pereira B.M.V., Rodrigues A.C. An update on efflux and uptake transporters as determinants of statin response. Expert Opinion on Drug Metabolism & Toxicology 2018; 14(6): 613–624. https://doi.org/10.1080/17425255.2018.1482276Rocha K.C., Pereira B.M.V., Rodrigues A.C. An update on efflux and uptake transporters as determinants of statin response. Expert Opinion on Drug Metabolism & Toxicology 2018; 14(6): 613–624. https://doi.org/10.1080/17425255.2018.1482276Zhang F., Lei X., Yang X. Emerging roles of ncRNAs regulating ABCC1 on chemotherapy resistance of cancer - a review. J Chemother. 2024; 36(1): 1-10. https://doi.org/10.1080/1120009X.2023.2247202.Zhang F., Lei X., Yang X. Emerging roles of ncRNAs regulating ABCC1 on chemotherapy resistance of cancer - a review. J Chemother. 2024; 36(1): 1-10. https://doi.org/10.1080/1120009X.2023.2247202.Sun J., Zhang H., Li L., et al. [Retracted] MicroRNA‑9 limits hepatic fibrosis by suppressing the activation and proliferation of hepatic stellate cells by directly targeting MRP1/ABCC1. Oncol Rep. 2023; 50(2): 153. https://doi.org/10.3892/or.2023.8590.Sun J., Zhang H., Li L., et al. [Retracted] MicroRNA‑9 limits hepatic fibrosis by suppressing the activation and proliferation of hepatic stellate cells by directly targeting MRP1/ABCC1. Oncol Rep. 2023; 50(2): 153. https://doi.org/10.3892/or.2023.8590.Chang C., Wang J., Wang H., Li J. Circ-ABCC1 enhances radioresistance of breast cancer cells via miR-627-5p/ABCC1 axis. Cell Mol Biol (Noisy-le-grand). 2022; 68(10): 187-192. https://doi.org/10.14715/cmb/2022.68.10.29.Chang C., Wang J., Wang H., Li J. Circ-ABCC1 enhances radioresistance of breast cancer cells via miR-627-5p/ABCC1 axis. Cell Mol Biol (Noisy-le-grand). 2022; 68(10): 187-192. https://doi.org/10.14715/cmb/2022.68.10.29.Yahya S.M.M., Nabih H.K., Elsayed G.H., et al. Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene. Breast Cancer Res Treat. 2024;204(1):133-149. https://doi.org/10.1007/s10549-023-07170-0.Yahya S.M.M., Nabih H.K., Elsayed G.H., et al. Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene. Breast Cancer Res Treat. 2024;204(1):133-149. https://doi.org/10.1007/s10549-023-07170-0.Li Y., Liu Y., Ren J., et al. miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma. J Neurooncol. 2018;138(3):499-508. https://doi.org/10.1007/s11060-018-2835-3.Li Y., Liu Y., Ren J., et al. miR-1268a regulates ABCC1 expression to mediate temozolomide resistance in glioblastoma. J Neurooncol. 2018;138(3):499-508. https://doi.org/10.1007/s11060-018-2835-3.Maslub M.G., Radwan M.A., Daud N.A.A., et al. Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?. Eur J Med Res 2023; 28: 381 (). https://doi.org/10.1186/s40001-023-01038-1Maslub M.G., Radwan M.A., Daud N.A.A., et al. Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?. Eur J Med Res 2023; 28: 381 (). https://doi.org/10.1186/s40001-023-01038-1Balasubramanian R., Maideen N.M.P. HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters - An overview. Curr Drug Metab. 2021; 22(5): 328-341. https://doi.org/10.2174/1389200222666210114122729Balasubramanian R., Maideen N.M.P. HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters - An overview. Curr Drug Metab. 2021; 22(5): 328-341. https://doi.org/10.2174/1389200222666210114122729Yee J, Kim H, Heo Y, Yoon HY, Song G, Gwak HS. Association between CYP3A5 Polymorphism and Statin-Induced Adverse Events: A Systemic Review and Meta-Analysis. J Pers Med. 2021; 11(7): 677. https://doi.org/10.3390/jpm11070677Yee J, Kim H, Heo Y, Yoon HY, Song G, Gwak HS. Association between CYP3A5 Polymorphism and Statin-Induced Adverse Events: A Systemic Review and Meta-Analysis. J Pers Med. 2021; 11(7): 677. https://doi.org/10.3390/jpm11070677Nakano M., Nakajima M. Current knowledge of microRNA-mediated regulation of drug metabolism in humans. Exp Opin Drug Metab Toxicol. 2018; 14(5): 493–504. https://doi.org/10.1080/17425255.2018.1472237Nakano M., Nakajima M. Current knowledge of microRNA-mediated regulation of drug metabolism in humans. Exp Opin Drug Metab Toxicol. 2018; 14(5): 493–504. https://doi.org/10.1080/17425255.2018.1472237Lodato N.J., Melia T., Rampersaud A., Waxman DJ. Sex-differential responses of tumor promotion-associated genes and dysregulation of novel long noncoding RNAs in constitutive androstane receptor-activated mouse liver. Toxicol Sci. 2017; 159(1): 25–41. https://doi.org/10.1093/toxsci/kfx114Lodato N.J., Melia T., Rampersaud A., Waxman DJ. Sex-differential responses of tumor promotion-associated genes and dysregulation of novel long noncoding RNAs in constitutive androstane receptor-activated mouse liver. Toxicol Sci. 2017; 159(1): 25–41. https://doi.org/10.1093/toxsci/kfx114Li D., Tolleson W.H., Yu D., et al. Regulation of cytochrome P450 expression by microRNAs and long noncoding RNAs: Epigenetic mechanisms in environmental toxicology and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2019; 37(3): 180-214. https://doi.org/10.1080/10590501.2019.Li D., Tolleson W.H., Yu D., et al. Regulation of cytochrome P450 expression by microRNAs and long noncoding RNAs: Epigenetic mechanisms in environmental toxicology and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 2019; 37(3): 180-214. https://doi.org/10.1080/10590501.2019.Lolodi O., Wang Y.M., Wright W.C., Chen T. Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017; 18(12): 1095-1105. https://doi.org/10.2174/1389200218666170531112038.Lolodi O., Wang Y.M., Wright W.C., Chen T. Differential regulation of CYP3A4 and CYP3A5 and its implication in drug discovery. Curr Drug Metab. 2017; 18(12): 1095-1105. https://doi.org/10.2174/1389200218666170531112038.Zhang S.Y., Surapureddi S., Coulter S., et al. Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver. Mol Pharmacol. 2012; 82(3): 529-540. https://doi.org/10.1124/mol.112.078386.Zhang S.Y., Surapureddi S., Coulter S., et al. Human CYP2C8 is post-transcriptionally regulated by microRNAs 103 and 107 in human liver. Mol Pharmacol. 2012; 82(3): 529-540. https://doi.org/10.1124/mol.112.078386.Tantawy M., Collins J.M., Wang D. Genome-wide microRNA profiles identify miR-107 as a top miRNA associating with expression of the CYP3As and other drug metabolizing cytochrome P450 enzymes in the liver. Front. Pharmacol. 2022; 13: 943538. https://doi.org/10.3389/fphar.2022.943538Tantawy M., Collins J.M., Wang D. Genome-wide microRNA profiles identify miR-107 as a top miRNA associating with expression of the CYP3As and other drug metabolizing cytochrome P450 enzymes in the liver. Front. Pharmacol. 2022; 13: 943538. https://doi.org/10.3389/fphar.2022.943538Baldán Á., de Aguiar Vallim T.Q. miRNAs and High-Density Lipoprotein metabolism. Biochim Biophys Acta. 2016; 1861(12 Pt B): 2053-2061. https://doi.org/10.1016/j.bbalip.2016.01.021,Baldán Á., de Aguiar Vallim T.Q. miRNAs and High-Density Lipoprotein metabolism. Biochim Biophys Acta. 2016; 1861(12 Pt B): 2053-2061. https://doi.org/10.1016/j.bbalip.2016.01.021,Jeon T.I., Osborne T.F. miRNA and cholesterol homeostasis. Biochim Biophys Acta. 2016; 1861 (12 Pt B): 2041-2046. https://doi.org/10.1016/j.bbalip.2016.01.005Jeon T.I., Osborne T.F. miRNA and cholesterol homeostasis. Biochim Biophys Acta. 2016; 1861 (12 Pt B): 2041-2046. https://doi.org/10.1016/j.bbalip.2016.01.005Andreou I., Sun X., Stone P.H., et al. miRNAs in atherosclerotic plaque initiation, progression, and rupture. Trends Mol Med. 2015; 21(5): 307-318. https://doi.org/10.1016/j.molmed.2015.02.003Andreou I., Sun X., Stone P.H., et al. miRNAs in atherosclerotic plaque initiation, progression, and rupture. Trends Mol Med. 2015; 21(5): 307-318. https://doi.org/10.1016/j.molmed.2015.02.003Fernández-Tussy P., Ruz-Maldonado I., Fernández-Hernando C. MicroRNAs and circular RNAs in lipoprotein metabolism. Curr Atheroscler Rep. 2021; 23(7): 33. https://doi.org/10.1007/s11883-021-00934-3Fernández-Tussy P., Ruz-Maldonado I., Fernández-Hernando C. MicroRNAs and circular RNAs in lipoprotein metabolism. Curr Atheroscler Rep. 2021; 23(7): 33. https://doi.org/10.1007/s11883-021-00934-3Aryal B., Singh A.K., Rotllan N., et al. MicroRNAs and lipid metabolism. Curr Opin Lipidol. 2017; 28(3): 273-280. https://doi.org/10.1097/MOL.0000000000000420,Aryal B., Singh A.K., Rotllan N., et al. MicroRNAs and lipid metabolism. Curr Opin Lipidol. 2017; 28(3): 273-280. https://doi.org/10.1097/MOL.0000000000000420,Wagschal A., Najafi-Shoushtari S.H., Wang L., et al. Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med. 2015; 21(11): 1290-1297. https://doi.org/10.1038/nm.3980,Wagschal A., Najafi-Shoushtari S.H., Wang L., et al. Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med. 2015; 21(11): 1290-1297. https://doi.org/10.1038/nm.3980,Keshavarz R., Reiner Ž., Zengin G., et al. MicroRNA-mediated regulation of LDL receptor: Biological and pharmacological implications. Curr Med Chem. 2024; 31(14): 1830-1838. https://doi.org/10.2174/0929867330666230407091652Keshavarz R., Reiner Ž., Zengin G., et al. MicroRNA-mediated regulation of LDL receptor: Biological and pharmacological implications. Curr Med Chem. 2024; 31(14): 1830-1838. https://doi.org/10.2174/0929867330666230407091652Zambrano T., Hirata R.D.C., Hirata M.H., et al. Statins differentially modulate microRNAs expression in peripheral cells of hyperlipidemic subjects: A pilot study. Eur J Pharm Sci. 2018; 117: 55-61. https://doi.org/10.1016/j.ejps.2018.02.007Zambrano T., Hirata R.D.C., Hirata M.H., et al. Statins differentially modulate microRNAs expression in peripheral cells of hyperlipidemic subjects: A pilot study. Eur J Pharm Sci. 2018; 117: 55-61. https://doi.org/10.1016/j.ejps.2018.02.007Cerda A., Bortolin R.H., Manriquez V., et al. Effect of statins on lipid metabolism-related microRNA expression in HepG2 cells. Pharmacol Rep. 2021; 73(3): 868-880. https://doi.org/10.1007/s43440-021-00241-3Cerda A., Bortolin R.H., Manriquez V., et al. Effect of statins on lipid metabolism-related microRNA expression in HepG2 cells. Pharmacol Rep. 2021; 73(3): 868-880. https://doi.org/10.1007/s43440-021-00241-3Feinberg M.W., Moore K.J. MicroRNA regulation of atherosclerosis. Circ Res. 2016; 118(4): 703-720. https://doi.org/10.1161/CIRCRESAHA.115.306300Feinberg M.W., Moore K.J. MicroRNA regulation of atherosclerosis. Circ Res. 2016; 118(4): 703-720. https://doi.org/10.1161/CIRCRESAHA.115.306300Chen H.L., Lo C.H., Huang C.C., et al. Galectin-7 downregulation in lesional keratinocytes contributes to enhanced IL-17A signaling and skin pathology in psoriasis. J Clin Invest. 2021; 131(1): e130740. https://doi.org/10.1172/JCI130740,Chen H.L., Lo C.H., Huang C.C., et al. Galectin-7 downregulation in lesional keratinocytes contributes to enhanced IL-17A signaling and skin pathology in psoriasis. J Clin Invest. 2021; 131(1): e130740. https://doi.org/10.1172/JCI130740,Wang F., Ma H., Liang W.J., et al. Lovastatin upregulates mi-croRNA-29b to reduce oxidative stress in rats with multiple car-diovascular risk factors. Oncotarget. 2017; 8(6): 9021-9034. https://doi.org/10.18632/oncotarget.14462.,Wang F., Ma H., Liang W.J., et al. Lovastatin upregulates mi-croRNA-29b to reduce oxidative stress in rats with multiple car-diovascular risk factors. Oncotarget. 2017; 8(6): 9021-9034. https://doi.org/10.18632/oncotarget.14462.,Yu F., Lv X.S., Jiang A.Y., et al. Pitavastatin ameliorates myocar-dial injury by inhibiting myocar-dial inflammation and ox-idative stress by modulating the mi-croRNA-106B-5p/mitogen-activated protein kinase kinase kinase 2 axis. J Physiol Phar-macol. 2024; 75(3). https://doi.org/10.26402/jpp.2024.3.03,Yu F., Lv X.S., Jiang A.Y., et al. Pitavastatin ameliorates myocar-dial injury by inhibiting myocar-dial inflammation and ox-idative stress by modulating the mi-croRNA-106B-5p/mitogen-activated protein kinase kinase kinase 2 axis. J Physiol Phar-macol. 2024; 75(3). https://doi.org/10.26402/jpp.2024.3.03,Jia M., Li Q., Guo J., et al. Deletion of BACH1 attenuates atherosclerosis by reducing endothelial inflammation. Circ Res. 2022; 130(7): 1038-1055. https://doi.org/10.1161/CIRCRESAHA.121.319540Jia M., Li Q., Guo J., et al. Deletion of BACH1 attenuates atherosclerosis by reducing endothelial inflammation. Circ Res. 2022; 130(7): 1038-1055. https://doi.org/10.1161/CIRCRESAHA.121.319540Lin H.J., Yu S.L., Su T.C., et al. Statin-induced microRNAome alterations modulating inflammation pathways of peripheral blood mononuclear cells in patients with hypercholesterolemia. Biosci Rep. 2020; 40(9): BSR20201885. doi:10.1042/BSR20201885Lin H.J., Yu S.L., Su T.C., et al. Statin-induced microRNAome alterations modulating inflammation pathways of peripheral blood mononuclear cells in patients with hypercholesterolemia. Biosci Rep. 2020; 40(9): BSR20201885. doi:10.1042/BSR20201885Sodi R., Eastwood J., Caslake M., et al. Relationship between circulating microRNA-30c with total- and LDL-cholesterol, their circulatory transportation and effect of statins. Clin Chim Acta. 2017; 466: 13-19. https://doi.org/10.1016/j.cca.2016.12.031Sodi R., Eastwood J., Caslake M., et al. Relationship between circulating microRNA-30c with total- and LDL-cholesterol, their circulatory transportation and effect of statins. Clin Chim Acta. 2017; 466: 13-19. https://doi.org/10.1016/j.cca.2016.12.031Ubilla C.G., Prado Y., Angulo J., et al. MicroRNA-33b is a potential non-Invasive biomarker for response to atorvastatin treatment in Chilean subjects with hypercholesterolemia: A pilot study. Front Pharmacol. 2021; 12: 674252 https://doi.org/10.3389/fphar.2021.674252,Ubilla C.G., Prado Y., Angulo J., et al. MicroRNA-33b is a potential non-Invasive biomarker for response to atorvastatin treatment in Chilean subjects with hypercholesterolemia: A pilot study. Front Pharmacol. 2021; 12: 674252 https://doi.org/10.3389/fphar.2021.674252,Saavedra K., Leal K., Saavedra N., et al. MicroRNA-20a-5p Downregulation by atorvastatin: A potential mechanism involved in lipid-lowering therapy. Int J Mol Sci. 2022; 23(9): 5022. https://doi.org/10.3390/ijms23095022Saavedra K., Leal K., Saavedra N., et al. MicroRNA-20a-5p Downregulation by atorvastatin: A potential mechanism involved in lipid-lowering therapy. Int J Mol Sci. 2022; 23(9): 5022. https://doi.org/10.3390/ijms23095022Mulchandani R., Lyngdoh T., Kakkar A.K. Statin use and safety concerns: an overview of the past, present, and the future. Expert Opin. Drug Saf. 2020; 19: 1011–1024. https://doi.org/10.1080/14740338.2020.1796966Mulchandani R., Lyngdoh T., Kakkar A.K. Statin use and safety concerns: an overview of the past, present, and the future. Expert Opin. Drug Saf. 2020; 19: 1011–1024. https://doi.org/10.1080/14740338.2020.1796966Bartel D. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281–297. https://doi.org/10.1016/s0092-8674(04)00045-5Bartel D. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116: 281–297. https://doi.org/10.1016/s0092-8674(04)00045-5Zhou L., Lim M.Y.T., Kaur P., et al. Importance of miRNA stability and alternative primary miRNA isoforms in gene regu-lation during Drosophila development. Elife. 2018; 7 https://doi.org/10.7554/eLife.38389.,Zhou L., Lim M.Y.T., Kaur P., et al. Importance of miRNA stability and alternative primary miRNA isoforms in gene regu-lation during Drosophila development. Elife. 2018; 7 https://doi.org/10.7554/eLife.38389.,Hartig S.M., Hamilton M.P., Bader D.A., McGuire S.E. The miRNA interactome in metabolic homeostasis. Trends Endocrinol. Metab. 2015; 26: 733–745. https://doi.org/10.1016/j.tem.2015.09.006Hartig S.M., Hamilton M.P., Bader D.A., McGuire S.E. The miRNA interactome in metabolic homeostasis. Trends Endocrinol. Metab. 2015; 26: 733–745. https://doi.org/10.1016/j.tem.2015.09.006Li C., Tian J., Liu N., et al. MicroRNA-206 as a potential cholesterol-lowering drug is superior to statins in mice. J Lipid Res. 2024; 65(7): 100576. https://doi.org/10.1016/j.jlr.2024.100576.Li C., Tian J., Liu N., et al. MicroRNA-206 as a potential cholesterol-lowering drug is superior to statins in mice. J Lipid Res. 2024; 65(7): 100576. https://doi.org/10.1016/j.jlr.2024.100576.Lv Y.C., Yang J., Yao F., et al. Diosgenin inhibits atherosclerosis via suppressing the MiR-19b-induced downregula-tion of ATP-binding cassette trans-porter A1. Atherosclerosis. 2015; 240(1): 80-89. https://doi.org/10.1016/j.atherosclerosis.2015.02.044Lv Y.C., Yang J., Yao F., et al. Diosgenin inhibits atherosclerosis via suppressing the MiR-19b-induced downregula-tion of ATP-binding cassette trans-porter A1. Atherosclerosis. 2015; 240(1): 80-89. https://doi.org/10.1016/j.atherosclerosis.2015.02.044Alvarez M.L., Khosroheidari M., Eddy E., Done S.C. MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis. Atherosclerosis. 2015; 242(2): 595-604. https://doi.org/10.1016/j.atherosclerosis.2015.08.023Alvarez M.L., Khosroheidari M., Eddy E., Done S.C. MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis. Atherosclerosis. 2015; 242(2): 595-604. https://doi.org/10.1016/j.atherosclerosis.2015.08.023Goedeke L., Rotllan N., Ramírez C.M., et al. miR-27b inhibits LDLR and ABCA1 expression but does not influence plasma and hepatic lipid levels in mice. Atherosclerosis. 2015; 243(2): 499-509. https://doi.org/10.1016/j.atherosclerosis.2015.09.033Goedeke L., Rotllan N., Ramírez C.M., et al. miR-27b inhibits LDLR and ABCA1 expression but does not influence plasma and hepatic lipid levels in mice. Atherosclerosis. 2015; 243(2): 499-509. https://doi.org/10.1016/j.atherosclerosis.2015.09.033Ru P., Guo D. microRNA-29 mediates a novel negative feedback loop to regulate SCAP/SREBP-1 and lipid metabolism. RNA Dis. 2017; 4(1): e1525. https://doi.org/10.14800/rd.1525Ru P., Guo D. microRNA-29 mediates a novel negative feedback loop to regulate SCAP/SREBP-1 and lipid metabolism. RNA Dis. 2017; 4(1): e1525. https://doi.org/10.14800/rd.1525Sidorkiewicz M. Is microRNA-33 an appropriate target in the treatment of atherosclerosis?. Nutrients. 2023; 15(4): 902 https://doi.org/10.3390/nu15040902Sidorkiewicz M. Is microRNA-33 an appropriate target in the treatment of atherosclerosis?. Nutrients. 2023; 15(4): 902 https://doi.org/10.3390/nu15040902Huang K., Pokhrel A., Echesabal-Chen J., et al. Inhibiting miR-33a-3p expression fails to enhance ApoAI-mediated choles-terol efflux in pro-inflammatory endothelial cells. Medicina (Kaunas). 2025; 61(2): 329. https://doi.org/10.3390/medicina61020329Huang K., Pokhrel A., Echesabal-Chen J., et al. Inhibiting miR-33a-3p expression fails to enhance ApoAI-mediated choles-terol efflux in pro-inflammatory endothelial cells. Medicina (Kaunas). 2025; 61(2): 329. https://doi.org/10.3390/medicina61020329Wang J., Hu X., Hu X., et al. MicroRNA-520c-3p targeting of RelA/p65 suppresses atherosclerotic plaque formation. Int J Biochem Cell Biol. 2021; 131: 105873. https://doi.org/10.1016/j.biocel.2020.105873Wang J., Hu X., Hu X., et al. MicroRNA-520c-3p targeting of RelA/p65 suppresses atherosclerotic plaque formation. Int J Biochem Cell Biol. 2021; 131: 105873. https://doi.org/10.1016/j.biocel.2020.105873Chen X., Liu Y., Zhou Q., et al. MiR-99a-5p up-regulates LDLR and functionally enhances LDL-C uptake via suppressing PCSK9 expression in human hepatocytes. Front Genet. 2024; 15: 1469094. https://doi.org/10.3389/fgene.2024.1469094Chen X., Liu Y., Zhou Q., et al. MiR-99a-5p up-regulates LDLR and functionally enhances LDL-C uptake via suppressing PCSK9 expression in human hepatocytes. Front Genet. 2024; 15: 1469094. https://doi.org/10.3389/fgene.2024.1469094Xu Y., Gao J., Gong Y., et al. Hsa-miR-140-5p down-regulates LDL receptor and attenuates LDL-C uptake in human hepatocytes. Atherosclerosis. 2020; 297: 111-119. https://doi.org/10.1016/j.atherosclerosis.2020.02.004Xu Y., Gao J., Gong Y., et al. Hsa-miR-140-5p down-regulates LDL receptor and attenuates LDL-C uptake in human hepatocytes. Atherosclerosis. 2020; 297: 111-119. https://doi.org/10.1016/j.atherosclerosis.2020.02.004Goedeke L., Rotllan N., Canfrán-Duque A., et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med. 2015; 21(11): 1280-1289. https://doi.org/10.1038/nm.3949Goedeke L., Rotllan N., Canfrán-Duque A., et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med. 2015; 21(11): 1280-1289. https://doi.org/10.1038/nm.3949Wang Y., Li F., Gao X., et al. miR-181d-5p ameliorates hypercholesterolemia by targeting PCSK9. J Endocrinol. 2024; 262(3): e230402. https://doi.org/10.1530/JOE-23-0402Wang Y., Li F., Gao X., et al. miR-181d-5p ameliorates hypercholesterolemia by targeting PCSK9. J Endocrinol. 2024; 262(3): e230402. https://doi.org/10.1530/JOE-23-0402Jiang H., Zhang J., Du Y., et al. microRNA-185 modulates low density lipoprotein receptor expression as a key posttran-scriptional regulator. Atherosclerosis. 2015; 243(2): 523-532. https://doi.org/10.1016/j.atherosclerosis.2015.10.026Jiang H., Zhang J., Du Y., et al. microRNA-185 modulates low density lipoprotein receptor expression as a key posttran-scriptional regulator. Atherosclerosis. 2015; 243(2): 523-532. https://doi.org/10.1016/j.atherosclerosis.2015.10.026Li C., Tian J., Liu N., et al. MicroRNA-206 as a potential cholesterol-lowering drug is superior to statins in mice. J Lipid Res. 2024; 65(7): 100576. https://doi.org/10.1016/j.jlr.2024.100576Li C., Tian J., Liu N., et al. MicroRNA-206 as a potential cholesterol-lowering drug is superior to statins in mice. J Lipid Res. 2024; 65(7): 100576. https://doi.org/10.1016/j.jlr.2024.100576Liu N., Tian J., Steer C.J., et al. MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux. Hepatology. 2025; 81(1): 111-125. https://doi.org/10.1097/HEP.0000000000000672Liu N., Tian J., Steer C.J., et al. MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux. Hepatology. 2025; 81(1): 111-125. https://doi.org/10.1097/HEP.0000000000000672Lu X., Yang B., Yang H., et al. MicroRNA-320b modulates cholesterol efflux and atherosclerosis. J Atheroscler Thromb. 2022; 29(2): 200-220. https://doi.org/10.5551/jat.57125Lu X., Yang B., Yang H., et al. MicroRNA-320b modulates cholesterol efflux and atherosclerosis. J Atheroscler Thromb. 2022; 29(2): 200-220. https://doi.org/10.5551/jat.57125Xu X., Dong Y., Ma N., et al. MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice. Me-tabolism. 2021; 119: 154768. https://doi.org/10.1016/j.metabol.2021.154768Xu X., Dong Y., Ma N., et al. MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice. Me-tabolism. 2021; 119: 154768. https://doi.org/10.1016/j.metabol.2021.154768Dong J., He M., Li J., et al. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production. JCI Insight. 2020; 5(23): e143812. https://doi.org/10.1172/jci.insight.143812Dong J., He M., Li J., et al. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production. JCI Insight. 2020; 5(23): e143812. https://doi.org/10.1172/jci.insight.143812Tanashyan M.M., Shabalina A.A., Kuznetsova P.I., Raskurazhev A.A. miR-33a and its association with lipid profile in pa-tients with carotid atherosclerosis. Int J Mol Sci. 2023; 24(7): 6376. https://doi.org/10.3390/ijms24076376Tanashyan M.M., Shabalina A.A., Kuznetsova P.I., Raskurazhev A.A. miR-33a and its association with lipid profile in pa-tients with carotid atherosclerosis. Int J Mol Sci. 2023; 24(7): 6376. https://doi.org/10.3390/ijms24076376Barut Z., Akdeniz F.T., Avsar O., Cabbar A.T. Investigation of miRNA-199a-5p expression and its clinical association with LDL Cholesterol levels in atherosclerosis. In Vivo. 2024; 38(6): 2656-2664. https://doi.org/10.21873/invivo.13742]Barut Z., Akdeniz F.T., Avsar O., Cabbar A.T. Investigation of miRNA-199a-5p expression and its clinical association with LDL Cholesterol levels in atherosclerosis. In Vivo. 2024; 38(6): 2656-2664. https://doi.org/10.21873/invivo.13742]Petrova М.М., Shnayder N.A., Dmitrenko D.V., et al. The pattern of circulating micrornas in acute myocardial infarction. Transbaikalian Medical Bulletin. 2025;(2):140-151. (In Russian) https://doi.org/10.52485/19986173_2025_2_140Petrova М.М., Shnayder N.A., Dmitrenko D.V., et al. The pattern of circulating micrornas in acute myocardial infarction. Transbaikalian Medical Bulletin. 2025;(2):140-151. (In Russian) https://doi.org/10.52485/19986173_2025_2_140Petrova M.M., Shnayder N.A., Petrov A.V., et al. MicroRNA-134-5p and the heart-brain axis. Siberian Medical Review. 2024;(6):14-18. https://doi.org/10.20333/25000136-2024-6-14-18Petrova M.M., Shnayder N.A., Petrov A.V., et al. MicroRNA-134-5p and the heart-brain axis. Siberian Medical Review. 2024;(6):14-18. https://doi.org/10.20333/25000136-2024-6-14-18Laffont B., Rayner K.J. MicroRNAs in the pathobiology and therapy of atherosclerosis. Can J Cardiol. 2017; 33(3): 313-324. https://doi.org/10.1016/j.cjca.2017.01.001Laffont B., Rayner K.J. MicroRNAs in the pathobiology and therapy of atherosclerosis. Can J Cardiol. 2017; 33(3): 313-324. https://doi.org/10.1016/j.cjca.2017.01.001Goedeke L., Wagschal A., Fernández-Hernando C., Näär A.M. miRNA regulation of LDL-cholesterol metabolism. Biochim Biophys Acta. 2016; 1861(12 Pt B): 2047-2052. https://doi.org/10.1016/j.bbalip.2016.03.007Goedeke L., Wagschal A., Fernández-Hernando C., Näär A.M. miRNA regulation of LDL-cholesterol metabolism. Biochim Biophys Acta. 2016; 1861(12 Pt B): 2047-2052. https://doi.org/10.1016/j.bbalip.2016.03.007Zaidi S.A., Fan Z., Chauhdari T., Ding Y. MicroRNA regulatory dynamic, emerging diagnostic and therapeutic frontier in atherosclerosis. Microvasc Res. 2025; 160: 104818. https://doi.org/10.1016/j.mvr.2025.104818Zaidi S.A., Fan Z., Chauhdari T., Ding Y. MicroRNA regulatory dynamic, emerging diagnostic and therapeutic frontier in atherosclerosis. Microvasc Res. 2025; 160: 104818. https://doi.org/10.1016/j.mvr.2025.104818Andreou I., Sun X., Stone P.H., et al. miRNAs in atherosclerotic plaque initiation, progression, and rupture. Trends Mol Med. 2015; 21(5): 307-318. https://doi.org/10.1016/j.molmed.2015.02.003Andreou I., Sun X., Stone P.H., et al. miRNAs in atherosclerotic plaque initiation, progression, and rupture. Trends Mol Med. 2015; 21(5): 307-318. https://doi.org/10.1016/j.molmed.2015.02.003Ganjali S., Aghaee-Bakhtiari S.H., Reiner Ž., Sahebkar A. Differential expression of miRNA-223 in coronary in-stent reste-nosis. J Clin Med. 2022; 11(3): 849. https://doi.org/10.3390/jcm11030849Ganjali S., Aghaee-Bakhtiari S.H., Reiner Ž., Sahebkar A. Differential expression of miRNA-223 in coronary in-stent reste-nosis. J Clin Med. 2022; 11(3): 849. https://doi.org/10.3390/jcm11030849Khan A.A., Gupta V., Mahapatra N.R. Key regulatory miRNAs in lipid homeostasis: Implications for cardiometabolic dis-eases and development of novel therapeutics. Drug Discov Today. 2022; 27(8): 2170-2180. https://doi.org/10.1016/j.drudis.2022.05.003Khan A.A., Gupta V., Mahapatra N.R. Key regulatory miRNAs in lipid homeostasis: Implications for cardiometabolic dis-eases and development of novel therapeutics. Drug Discov Today. 2022; 27(8): 2170-2180. https://doi.org/10.1016/j.drudis.2022.05.003Della Corte V., Todaro F., Cataldi M., Tuttolomondo A. Atherosclerosis and its related laboratory biomarkers. Int J Mol Sci. 2023; 24(21): 15546. https://doi.org/10.3390/ijms242115546Della Corte V., Todaro F., Cataldi M., Tuttolomondo A. Atherosclerosis and its related laboratory biomarkers. Int J Mol Sci. 2023; 24(21): 15546. https://doi.org/10.3390/ijms242115546Gorabi A.M., Ghanbari M., Sathyapalan T., et al. Implications of microRNAs in the pathogenesis of atherosclerosis and prospects for therapy. Curr Drug Targets. 2021; 22(15): 1738-1749. https://doi.org/10.2174/1389450122666210120143450Gorabi A.M., Ghanbari M., Sathyapalan T., et al. Implications of microRNAs in the pathogenesis of atherosclerosis and prospects for therapy. Curr Drug Targets. 2021; 22(15): 1738-1749. https://doi.org/10.2174/1389450122666210120143450Myocardial infarction and vascular cognitive disorders / Edited by M.M. Petrova, N.A. Shnayder. Saint Petersburg: DEAN Publishing House, 2025. 528 p. ISBN 978-5-6052545-0-8. eLIBRARY ID: 83153049 EDN: ZNZIJN (In Russian)Myocardial infarction and vascular cognitive disorders / Edited by M.M. Petrova, N.A. Shnayder. Saint Petersburg: DEAN Publishing House, 2025. 528 p. ISBN 978-5-6052545-0-8. eLIBRARY ID: 83153049 EDN: ZNZIJN (In Russian)Shnayder N.A., Bader V.V., Nasyrova R.F. Prospects of pharmacotranscriptomics in understanding the effects of antiepileptic drugs and searching for new classes of antiepileptic drugs. Pharmacogenetics and Pharmacogenomics. 2025; 4: 10-17. (In Russian). https://doi.org/10.37489/2588-0527-2025-4-10-17Shnayder N.A., Bader V.V., Nasyrova R.F. Prospects of pharmacotranscriptomics in understanding the effects of antiepileptic drugs and searching for new classes of antiepileptic drugs. Pharmacogenetics and Pharmacogenomics. 2025; 4: 10-17. (In Russian). https://doi.org/10.37489/2588-0527-2025-4-10-17Shnayder N.A., Pekarets N.A., Pekarets N.I., et al. The role of microRNAs as regulators of systemic inflammatory response in anticonvulsant-induced metabolic syndrome. Epilepsy and Paroxysmal Conditions. 2025; 17 (2): 208–226. (In Russian). https://doi.org/10.17749/2077-8333/epi.par.con.2025.239Shnayder N.A., Pekarets N.A., Pekarets N.I., et al. The role of microRNAs as regulators of systemic inflammatory response in anticonvulsant-induced metabolic syndrome. Epilepsy and Paroxysmal Conditions. 2025; 17 (2): 208–226. (In Russian). https://doi.org/10.17749/2077-8333/epi.par.con.2025.239

The authors declare that there are no conflicts of interest present.